Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer
Author:
Publisher
S. Karger AG
Subject
Cancer Research,Oncology,General Medicine
Reference77 articles.
1. Cancer Statistics, 2005
2. National Comprehensive Cancer Network guidelines for the management of prostate cancer
3. Mechanisms of Androgen-Refractory Prostate Cancer
4. Clinical Trials in Relapsed Prostate Cancer: Defining the Target
5. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dual action of NSC606985 on cell growth and apoptosis mediated through PKCδ in prostatic cancer cells;International Journal of Oncology;2017-09-27
2. Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression;Molecular Cancer Therapeutics;2017-06-14
3. Chapter 6 Plumbagin and Prostate Cancer Therapy;Traditional Herbal Medicines for Modern Times;2016-12
4. Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer;Oncotarget;2015-04-12
5. Immunotherapeutic approaches targeting prostate cancer and its microenvironment;memo - Magazine of European Medical Oncology;2012-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3